Brief: Morphotek announces agreement with Fujirebio Diagnostics to commercialize CA125 II assay as companion diagnostic for Farletuzumab
05/09/2017 15:02
Sept 5 (Reuters) - Morphotek:
* Announces agreement with Fujirebio Diagnostics, Inc. to
commercialize CA125 II assay as a companion diagnostic for
Farletuzumab
* Agreement provides Fujirebio with worldwide license to
develop, manufacture and commercialize CA125 II assay as a
companion diagnostic
Source text for Eikon: urn:newsml:reuters.com:*:nPn2c4rwa
Further company coverage: 4523.T 4544.T
((Bangalore.newsroom@thomsonreuters.com;))